Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
Authors: P. P. Sfikakis, P. H. Kaklamanis, A. Elezoglou, N. Katsilambros, P. G. Theodossiadis, S. Papaefthimiou, N. Markomichelakis
Journal: Annals of Internal Medicine (2004)

Letters2 March 2004Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet DiseaseP. P. Sfikakis, MD, P. H. Kaklamanis, MD, A. Elezoglou, MD, N. Katsilambros, MD, P. G. Theodossiadis, MD, S. Papaefthimiou, MD, and N. Markomichelakis, MDP. P. Sfikakis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., P. H. Kaklamanis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., A. Elezoglou, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., N. Katsilambros, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., P. G. Theodossiadis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., S. Papaefthimiou, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece., and N. Markomichelakis, MDFrom Laikon Hospital, Athens University Medical School, 15452 Athens, Greece.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-5-200403020-00025 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Background: In Adamantiades–Behçet disease, recurrent ocular inflammation may lead to loss of vision despite continuous immunosuppressive therapy (1-3). Preliminary evidence suggests that the anti–tumor necrosis factor (TNF) monoclonal antibody infliximab rapidly controls sight-threatening inflammation, a critical factor in avoiding chronic, irreversible retinal lesions (4, 5).Objective: In this open, prospective study, we report on 25 patients who were treated with a single infliximab infusion at the immediate onset of a relapse. The primary outcome measure was the time to complete suppression of ocular inflammation. We also report on 15 of these patients who had experienced at least ...References1. Kaklamani VG, Vaiopoulos G, Kaklamanis PG. Behçet's disease. Semin Arthritis Rheum. 1998;27:197-217. [PMID: 9514126] CrossrefMedlineGoogle Scholar2. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al . Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130:492-513. [PMID: 11024423] CrossrefMedlineGoogle Scholar3. Kaklamani VG, Kaklamanis PG. Treatment of Behçet's disease—an update. Semin Arthritis Rheum. 2001;30:299-312. [PMID: 11303303] CrossrefMedlineGoogle Scholar4. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behçet's disease [Letter]. Lancet. 2001;358:295-6. [PMID: 11498218] CrossrefMedlineGoogle Scholar5. Sfikakis PP. Behçet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002;61 Suppl 2 ii51-3. [PMID: 12379622] CrossrefMedlineGoogle Scholar6. Sfikakis PP, Kollias G. Tumor necrosis factor biology in experimental and clinical arthritis. Curr Opin Rheumatol. 2003;15:380-6. [PMID: 12819464] CrossrefMedlineGoogle Scholar7. Toker E, Kazokoglu H, Acar N. High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease. Br J Ophthalmol. 2002;86:521-3. [PMID: 11973245] CrossrefMedlineGoogle Scholar8. Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, et al . Interferon alfa-2a in the treatment of Behçet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-71. [PMID: 11939808] CrossrefMedlineGoogle Scholar9. Gorman JD, Sack KE, Davis JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med. 2002;346:1349-56. [PMID: 11986408] CrossrefMedlineGoogle Scholar10. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, et al . Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807-13. [PMID: 12632436] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Laikon Hospital, Athens University Medical School, 15452 Athens, Greece. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByAdvances in the Treatment of Behcet's DiseaseTreatment of Neuro-Behçet's DiseaseAdamantiades–Behçet's DiseaseEffectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical FeaturesBehçet's disease uveitis: is there a need for new emerging drugs?Neuro-Behcet Disease and Ocular Inflammation: A Case Report and Literature ReviewThe current status of biological treatment for uveitisWeak association of a TNFRSF1A polymorphism with Behcet's disease in Chinese HanEffectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets' Disease-Associated Uveitis: A Systematic Review and Meta-AnalysisDisease ManagementEye Disease in Behçet SyndromeAutoimmune and Autoantibody-Associated EncephalomyelopathiesSystemic immunosuppressive therapies for uveitis in developing countriesThe use of biologic agents in the management of uveitisThe efficacy of systemic and intravitreal infliximab treatments in an endotoxin-induced uveitis modelThe Greek (Hellenic) rheumatology over the years: from ancient to modern timesExpert opinion on the use of biological therapy in non-infectious uveitisBiologics for the treatment of noninfectious uveitisBiologic Treatment Options for Retinal Neovascularization in Behçet's DiseaseAdamantiades-Behçet's DiseaseAnti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitisManagement of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendationsAvis d'experts pour le traitement des uvéites non infectieusesBehçet's disease: New insights into pathophysiology, clinical features and treatment options2018 update of the EULAR recommendations for the management of Behçet's syndromeAn update on the use of biologic therapies in the management of uveitis in Behçet's disease: a comprehensive reviewManagement of severe complications in Behçet's disease with TNF inhibitorsAnti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitisBehçet syndrome: from pathogenesis to novel therapiesBehçet DiseaseApplication of multiplex immunoassay technology to investigations of ocular diseaseDiagnostic Validity of Minor Salivary Gland Biopsies in Behçet's Disease and Sjögren's SyndromeNew Immunosuppressive Therapies in Uveitis TreatmentCogan and Behcet SyndromesBiological Response Modifiers in the Treatment of Noninfectious UveitisClinical Trials in Noninfectious UveitisBehçet's syndrome: New insights into pathogenesis and managementEvidence-based practice in Behçet's disease: identifying areas of unmet need for 2014Biotherapies in Behçet's diseaseManagement of Behçet's syndromeUpdate on the therapy of Behçet diseaseCurrent and future treatments for Behçet's uveitis: road to remissionTraitement de la maladie de BehçetTherapy of Ocular Behçet DiseaseUse of infliximab and other biologics in Behçet diseaseSystemic therapies for inflammatory eye disease: Past, Present and FutureLocal therapies for inflammatory eye disease in translation: past, present and futureLong-term Clinical Outcomes in Patients with Refractory Uveitis Associated with Behçet Disease Treated with InfliximabCase of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 yearsApproaches to immunosuppression in Behçet's diseaseLight on the Horizont: biologicals in Behçet uveitisMorbus Behçet – ophthalmologische und allgemeine AspekteSystematic Review of Anti-Tumor Necrosis Factor-alpha Therapy for Treatment of Immune-mediated UveitisPsoriasis triggered by infliximab in a patient with Behçet's diseaseBehcet's SyndromeIntravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Behçet Disease: A Pilot Study in 15 PatientsInflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammationThe role of biologic agents in the management of non-infectious uveitisCorrelation between elevation of serum antinuclear antibody titer and decreased therapeutic efficacy in the treatment of Behçet's disease with infliximabLong-Term Efficacy and Safety of Infliximab in the Treatment of Behçet's DiseaseBiological agents for the treatment of uveitisEfficacy of tumour necrosis factor-α antagonists in aphthous ulceration: review of published individual patient dataFármacos anti-TNF y uveítis anterioresMaladie de BehçetUtilisation des anti-TNF-α dans les uvéites au CHU de BesançonSystemic Therapy With Conventional and Novel Immunomodulatory Agents for Ocular Inflammatory DiseaseReview and update of intraocular therapy in noninfectious uveitisThe Use of Biologic Agents in the Treatment of Ocular Manifestations of Behcet's DiseaseAnti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 PatientsBehçet's syndrome and micro-organismsSystematic Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment of Autoimmune Posterior UveitisBehçet's Syndrome: Clinical Presentations Affecting Prognosis and SurvivalAnti-TNF-Therapie bei UveitisEfficacy of Infliximab Therapy for a Patient with Superficial Thrombophlebitis and Rheumatoid ArthritisAzathioprine in severe uveitis of Behçet's diseaseSafety and Effectiveness of Interferon Alpha-2a in Treatment of Patients with Behçet's Uveitis Refractory to Conventional TreatmentsClinical Experience with Adalimumab in the Treatment of Ocular Behçet DiseaseBiologic therapy for uveitisMedical Management of Behçet's SyndromeEye Disease in Behçet's SyndromeManagement of Sarcoidosis, Behçet's Disease, and Other Rare Rheumatic DiseasesINFLIXIMAB STABILITY AFTER RECONSTITUTION, DILUTION, AND STORAGE UNDER REFRIGERATIONMore Questions Than Answers: A Call for a Moratorium on the Use of Intravitreal Infliximab Outside of a Well-Designed TrialAcute aseptic meningitis and diffuse myelitis as the presenting features of neurological Behcet diseaseMaladie de Behçet : les nouvelles thérapeutiquesClinical Review: Anti-TNFα Therapies in Uveitis: Perspective on 5 Years of Clinical ExperienceShort-term Results of a Single Intravitreal Bevacizumab (Avastin) Injection versus a Single Intravitreal Triamcinolone Acetonide (Kenacort) Injection for the Management of Refractory Noninfectious Uveitic Cystoid Macular EdemaBehçet's disease: an algorithmic approach to its treatmentINTRAVITREAL INJECTION OF THERAPEUTIC AGENTSUvéites et médecine interne : stratégies diagnostique et thérapeutiqueInfliximab for the treatment of active scleritisIntravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular DegenerationBehçet's disease – a contemporary reviewTraitements anti-TNFα dans les maladies auto-immunes et/ou inflammatoires systémiquesIntravitreal administration of the anti-TNF monoclonal antibody Infliximab in the rabbitTreatment of refractory posterior uveitis with infliximab: a 7‐year follow‐up studyInduction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 casesTreatment strategies for Behçet's diseaseSafety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trialImmunosuppressive therapy for ocular diseasesA Systematic Review of the Off-Label Use of Biological Therapies in Systemic Autoimmune DiseasesUse of laser flare-cell photometry to quantify intraocular inflammation in patients with Behçet UveitisBiologic agents in the management of inflammatory eye diseasesDrug Insight: anti-tumor necrosis factor therapies for the vasculitic diseasesTraitements actuels et perspectives thérapeutiques dans la maladie de BehçetAdamantiades–Behçet's DiseaseBEHÇET DISEASE 136.1Biologic Response Modifier Therapy for Psoriatic Ocular Inflammatory DiseaseA Review of Pediatric Uveitis: Part II. Autoimmune Diseases and Treatment ModalitiesTerapia biológica con anticuerpos anti factor de necrosis tumoral, ¿ampliando el espectro de sus indicaciones?Anti-TNF- Therapy in Seven Patients with Behcet's Uveitis: Advantages and Controversial AspectsInfliximab Treatment for Ocular and Extraocular Manifestations of Behçet's DiseaseTUMOR NECROSIS FACTOR ANTAGONISTSStandard and Novel Therapeutic Approaches to Behçet's DiseaseTherapeutic Effects of Anti-Tumor Necrosis Factor Monoclonal Antibody on Experimental UveitisRisk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agentsBehçet's disease: general concepts and recent advancesLong-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's diseasePossibility of inducing anterior chamber-associated immune deviation by TGF-β2 treatment of monocytes isolated from Behcet's patientsIntraocular Cytokine Environment in Active Behçet UveitisTumour necrosis factor α inhibitors in the treatment of childhood uveitisExtended indications for anti-tumor necrosis factor-α therapyNeovascularization of the Optic Disc in Behçet's DiseaseUveitisPsoriasis occurring during anti-TNF-α therapy: causal effect or unrelated?Promising new therapies for Behcet's diseaseImmunomodulatory Therapy for the Treatment of Ocular Inflammatory Disease: Evidence-based Medicine Recommendations for UseBeh??et DiseaseBiologic therapies for inflammatory eye diseaseNewer Therapeutic Approaches to the Vasculitides: Biologic AgentsNewer Therapeutic Approaches: Spondyloarthritis and UveitisNew approaches in the treatment of Adamantiades-Behçet's diseaseTratamiento a medio y largo plazo con infliximab y metotrexato en uveítis posteriores y/o crónicas rebeldes al tratamiento convencionalTreatment of Behcets diseaseTreatment of Behçet's diseaseLes manifestations oculaires de la maladie de Behçet (étude de 50 patients consultant en dermatologie)Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet's disease: An open-label trialPsoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reactionAnti-TNF-α therapy for uveitis: Behçet and beyondCurrent Concepts in the Etiology and Treatment of Behçet DiseaseTNF?-Inhibitoren in der UveitistherapieMorbus Adamantiades-Beh�etRegression of neovascular age-related macular degeneration following infliximab therapyAplicaciones de anticuerpos monoclonales y productos de biotecnología en el tratamiento de las enfermedades inflamatorias crónicasRegression of Sight-Threatening Macular Edema in Type 2 Diabetes Following Treatment With the Anti-Tumor Necrosis Factor Monoclonal Antibody InfliximabInfliximab for chronic cystoid macular edema associated with uveitisReview of immunosuppressive drug therapy in uveitisImmune Mechanisms in UveitisTumor Necrosis Factor Alpha-Targeted Therapies in Uveitis 2 March 2004Volume 140, Issue 5Page: 404-406KeywordsCyclophosphamideEye diseasesImmunosuppressivesInflammationLesionsRetinitisTumor necrosis factorVasculitisVisionVisual acuity ePublished: 2 March 2004 Issue Published: 2 March 2004 CopyrightCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...